A detailed history of Hudson Bay Capital Management LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 220,000 shares of ARWR stock, worth $4.28 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
220,000
Previous 180,000 22.22%
Holding current value
$4.28 Million
Previous $4.68 Million 8.96%
% of portfolio
0.02%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.36 - $29.54 $774,400 - $1.18 Million
40,000 Added 22.22%
220,000 $4.26 Million
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $984,150 - $1.27 Million
45,000 Added 33.33%
180,000 $4.68 Million
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $2.91 Million - $4.22 Million
-106,807 Reduced 44.17%
135,000 $3.86 Million
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $1.73 Million - $2.54 Million
81,807 Added 51.13%
241,807 $7.4 Million
Q3 2023

Nov 14, 2023

BUY
$26.2 - $36.08 $1.24 Million - $1.71 Million
47,500 Added 42.22%
160,000 $4.3 Million
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $880,600 - $1.45 Million
-35,000 Reduced 23.73%
112,500 $4.01 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $3.49 Million - $5.68 Million
147,500 New
147,500 $3.75 Million
Q2 2022

Aug 12, 2022

SELL
$27.79 - $50.61 $933,299 - $1.7 Million
-33,584 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $1.33 Million - $2.35 Million
33,584 New
33,584 $1.55 Million
Q3 2020

Nov 12, 2020

SELL
$33.21 - $51.27 $1.16 Million - $1.79 Million
-35,000 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$26.12 - $43.27 $914,200 - $1.51 Million
35,000 New
35,000 $1.51 Million
Q1 2019

May 15, 2019

SELL
$12.05 - $20.18 $361,500 - $605,400
-30,000 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$10.74 - $19.7 $322,200 - $591,000
30,000 New
30,000 $373,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.06B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.